Gund Tamara M, Floyd Jie, Jung Dawoon
Department of Chemistry, Chemical Engineering and Environmental Science, New Jersey Institute of Technology, University Heights, Newark, NJ 07102, USA.
J Mol Graph Model. 2004 Jan;22(3):221-30. doi: 10.1016/j.jmgm.2003.08.001.
We have performed molecular modeling studies on several sigma 1 specific ligands, including PD144418, spipethiane, haloperidol, pentazocine, and others to develop a pharmacophore for sigma 1 receptor-ligand binding, under the assumption that all the compounds interact at the same receptor binding site. The modeling studies have investigated the conformational and electrostatic properties of the ligands. Superposition of active molecules gave the coordinates of the hypothetical 5-point sigma 1 pharmacophore, as follows: R1 (0.85, 7.26, 0.30); R2 (5.47, 2.40, -1.51); R3 (-2.57, 4.82, -7.10); N (-0.71, 3.29, -6.40); carbon centroid (3.16, 4.83, -0.60), where R1, R2 were constructed onto the aromatic ring of each compound to represent hydrophobic interactions with the receptor; and R3 represents a hydrogen bond between the nitrogen atom and the receptor. Additional analyses were used to describe secondary binding sites to electronegative groups such as oxygen or sulfur atom. Those coordinates are (2.34, 5.08, -4.18). The model was verified by fitting other sigma 1 receptor ligands. This model may be used to search conformational databases for other possibly active ligands. In conjunction with rational drug design techniques the model may be useful in design and synthesis of novel sigma 1 ligands of high selectivity and potency. Calculations were performed using Sybyl 6.5.
我们对几种σ1特异性配体进行了分子建模研究,包括PD144418、螺哌噻吨、氟哌啶醇、喷他佐辛等,目的是在假设所有化合物都在同一受体结合位点相互作用的前提下,开发一种用于σ1受体 - 配体结合的药效团。建模研究考察了这些配体的构象和静电性质。活性分子的叠加给出了假设的五点σ1药效团的坐标,如下:R1(0.85, 7.26, 0.30);R2(5.47, 2.40, -1.51);R3(-2.57, 4.82, -7.10);N(-0.71, 3.29, -6.40);碳质心(3.16, 4.83, -0.60),其中R1、R2构建在每个化合物的芳香环上,代表与受体的疏水相互作用;R3代表氮原子与受体之间的氢键。还进行了额外分析以描述与氧或硫原子等电负性基团的二级结合位点。这些坐标为(2.34, 5.08, -4.18)。该模型通过拟合其他σ1受体配体进行了验证。此模型可用于在构象数据库中搜索其他可能具有活性的配体。结合合理药物设计技术,该模型可能有助于设计和合成具有高选择性和高效力的新型σ1配体。计算使用Sybyl 6.5进行。